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The association between HLA-B27 and the group of autoimmune inflammatory arthritic diseases, the spondyloarthropathies
(SpAs) which include ankylosing spondylitis (AS) and Reactive Arthritis (ReA), has been well established and remains the strongest
association between any HLA molecule and autoimmune disease. The mechanism behind this striking association remains elusive;
however animal model and biochemical data suggest that HLA-B27 misfolding may be key to understanding its association with
the SpAs. Recent investigations have focused on the unusual biochemical structures of HLA-B27 and their potential role in SpA
pathogenesis. Here we discuss how these unusual biochemical structures may participate in cellular events leading to chronic
inflammation and thus disease progression.
1. Introduction
The association between HLA-B27 and the group of autoim-
mune inflammatory arthritic conditions referred to collec-
tively as the Spondyloarthropathies (SpAs) is well established
and has been known for over 30 years [1, 2]. Of all the
SpAs, Ankylosing Spondylitis (AS) exhibits the strongest
association with HLA-B27. Within the UK, the current
Arthritis Research UK estimates for the number of AS cases
are between 116–318,000 (male) and 29–87,000 (female)
(http://www.arthritisresearchuk.org/research/data on arth-
ritis/data on as.aspx) of which 95% are HLA-B27+. Reactive
arthritis (ReA), an SpA where joint inflammation develops
following certain bacterial infections, such as Salmonella and
Chlamydia, has an association with HLA-B27 up to 80%
[3]. The SpAs are multisystemic in nature, and the major
targets of the disease are axial and peripheral joints (which
in its severest form can lead to bone fusion of the sacroiliac
joint), entheses (points of ligament, tendon and joint capsule
insertion into bone), skin (psoriasis or psoriasis-like lesions),
mucosa, gut (inflammatory bowel disease), urinogenital
tract, and eyes.
2. HLA-B27 and the Spondyloarthropathies
The Human Leukocyte Antigen (HLA)-B27 is a Major His-
tocompatibility Complex (MHC) class I molecule encoded
within the HLA-B locus. MHC class I molecules present
peptides, derived from intracellular antigens, to CD8+ cyto-
toxic T cells, and act as ligands for Natural Killer cells. Like
other MHC class I molecules it is a glycoprotein that folds
within the lumen of the endoplasmic environment (ER). It
is composed of a heavy chain noncovalently associated with
the light chain beta-2-microglobulin (β2m) and loaded with
a 8–13 amino acid long peptide before expression at the cell
surface [4].
The most significant observation implicating the direct
involvement of HLA-B27 in SpAs has come from HLA-B27
transgenic rats. Several HLA-B27-human β2m rat transgenic
lines developed a spontaneous multisystemic inflammatory
arthritic disorder with many features of human AS [5,
6]. However, the rat transgenic models do exhibit subtle
diﬀerences to human AS, such as the order of appearance and
frequency of certain disease features. Transmission of disease
has remained stable through the generations, and most
backgrounds tested, Lewis, Fisher, and PVG, are permissive
whilst the Dark agouti strain is resistant. Therefore, like
the human disease, other susceptibility genes are probably
involved [6, 7].
There are two main theories which attempt to explain
the link between HLA-B27 and the SpAs. The first is the
“arthritogenic peptide hypothesis” which postulates that
specific pathogenic peptide(s) derived from the target organ
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Figure 1: Schematic illustrating the basic outline of the ER stress pathways. The eﬀector molecules of the UPR, the transcription factor
ATF6, and the kinases IRE1 and PERK are held in an inactive state via their association with the ER chaperone BiP. On sensing misfolding,
BiP dissociates from these eﬀector molecules. This results in ATF6 traﬃcking to the Golgi where two Golgi resident proteases cleave the ATF6
cytosolic domain which acts as a transcription factor activating folding chaperones. IRE1 oligomerises and autophosphorylates, which can
splice the 26-base pair intronic sequence from XBP1 mRNA, which is then religated and encodes for a potent transcription factor. XBP1
induces the production of chaperones and proteins involved in protein folding or degradation. PERK oligomerises and autophosphorylates
which in turn phosphorylates the elongation factor 2α that inhibits protein translation. PERK can activate ATF4 and CHOP which can
activate apoptosis. Since being reported, little is known about the EOR, which is thought to detect a build-up of proteins within the ER and
activate NF-κB, which can target proinflammatory cytokine production.
are presented to self-reactive T cells [8]. A variation on this
theme of antigen processing is “molecular mimicry” where
a cross-reactive peptide derived from an infecting bacterial
pathogen stimulates T cells that can respond to an HLA-B27
associated “self-peptide” or to peptides derived from HLA-
B27 itself [8]. The second hypothesis proposes that certain
biochemical characteristics of HLA-B27, mainly its ability
to misfold, were the main contributory factor leading to
SpA development [9–11]. This latter idea is referred to as
the “misfolding hypothesis” and is the main focus of this
paper.
3. The Misfolding Hypothesis
The misfolding hypothesis postulates that HLA-B27 can
misfold within the environment of the ER and lead to a “gain
of toxicity function” by inducing cellular stress responses.
These responses are known as the unfolded protein response
(UPR) and the ER overload response (EOR). This in
turn would perturb normal cellular function and lead to
proinflammatory cytokine production contributing to SpA
development [10]. The misfolding hypothesis has led to
the interesting notion that the SpAs could be reclassified as
autoinflammatory rather than autoimmune in nature. Such
autoinflammatory diseases are characterized by inflamma-
tion in the absence of autoantibodies and antigen specific-T
cells, which are two criteria that the SpAs seemingly fullfill
[12].
The origins of the misfolding hypothesis stemmed from
a key biological observation made in the mid-1990s. In
yeast and later in mammalian cells, it was shown that by
disrupting global protein folding within the ER, cellular
events trigger activation of genes and production of proteins
whose functions aim at restoring ER homeostasis [13, 14].
These cellular stress responses are referred to as ER stress
responses, of which there are two types, the Unfolded
Protein Response (UPR) and ER Overload Response (EOR)
(Figure 1). The UPR aims to restore ER homeostasis whilst
dealing with misfolded proteins, while the EOR attempts
to restore normal ER function during the handling of
accumulating protein.
There are three main eﬀector molecules of the UPR,
the ATF6 transcription factor and the two kinases IRE1
and PERK [14–16]. These eﬀector molecules reside within
the ER and are maintained in an inactive state by the
ER resident chaperone Immunoglobulin Binding Protein
(BiP). During ER stress, BiP is sequestered away from
these eﬀector molecules, leading to their activation [17–19]
(Figure 1).
Dissociation from BiP unmasks targeting signals, which
translocate ATF6 to the Golgi apparatus. Within the Golgi
apparatus, proteolytic processing of the ATF6 cytosolic
domain by two resident proteases SP1 and 2 occurs [17,
20]. The ATF6 cytosolic domain is then translocated to the
nucleus and acts as a potent transcription factor upregu-
lating chaperones participating in protein folding [20, 21].
Prolonged ER stress can induce the oligomerisation and
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autophosphorylation of the ER resident IRE1 and PERK
kinases [22]. Phosphorylated IRE1 can splice the cytoso-
lically located XBP1 mRNA by removing a 26-nucleotide
intronic sequence which then generates the potent XBP-
1 spliced(s) transcription factor [23]. XBP1s can activate
chaperones to enhance cellular folding capacity and/or
proteins involved in degradation of misfolding substrates
[24]. Activated PERK can phosphorylate elongation factor 2α
(eF2α), which inhibits protein synthesis, thus reducing the
protein load within the ER [25, 26]. Furthermore PERK can
activate a series of transcription factors (ATF4 and CHOP)
which can lead to the induction of apoptosis, thus leading to
the removal of terminally distressed cells [27–30].
The ER overload response remains poorly defined, but
it is thought that accumulation of misfolded proteins within
the ER leads to the activation of the transcription factor NF-
κB [31, 32] (Figure 1). As NF-κB can target proinflamma-
tory cytokine genes, activation of this transcription factor
could be a key link between HLA-B27 misfolding and the
production of proinflammatory cytokines. However, since
the proposition of these ER stress pathways, in stark contrast
to the UPR, which has been well characterized, the EOR
remains ill defined.
Perhaps themost significant finding demonstrating a link
between elevated ER stress induction and the production of
proinflammatory mediators and cytokines came from the
demonstration that ER stress within the liver led to the
activation of the transcription factor, CREBH, which is a
member of the same family of b-ZiP transcription factors
to which ATF6 belongs. CREBH activation directly led to
enhanced production of proinflammatory mediators [33].
Subsequently, other transcription factors of the ER stress
pathway can be involved in proinflammatory cytokine pro-
duction such as XBP-1 [34] and CHOP [35]. Furthermore,
proinflammatory cytokines, notably TNFα, can induce ER
stress [36, 37]. This raises the possibility that, if HLA-
B27 misfolding does induce ER stress and lead to proin-
flammatory cytokine production, this could develop into a
positive feedback loop which exacerbates and perpetuates
the release of TNFα and other pro-inflammatory mediators.
Thus there does indeed appear to be a link between ER stress
and a proinflammatory cytokine environment, which is a
characteristic feature of AS patients.
4. The Misfolding Hypothesis and
HLA-B27 Rat Transgenic Models
Certain features of the rat model suggest that antigen
presentation by HLA-B27 alone cannot be responsible for
disease. Firstly, there is a strict correlation between sus-
ceptibility to disease and levels of HLA-B27 as determined
by transgene copy number. A threshold of HLA-B27 copy
number exists above which disease predictably arises [38].
However, such copy number dependency calls into question
whether disease in rats was specific or merely a toxic side
eﬀect of transgene overexpression. Disease development was
HLA-B27 specific as HLA-B7 rats with an identical copy
number failed to develop any pathology [6]. Intriguingly,
one human study demonstrated that elevated levels of HLA-
B27 within AS patients could be a determining factor in
disease development [39]. Further studies established that
some features of the rat SpAs could be transferred to
both HLA-B27 disease resistant and nontransgenic recipients
by bone marrow engraftment of immature hematopoietic
cells [40]. Of the disease features, it was the associated
colitis and psoriasiform skin lesions that were predominantly
transferred by bone marrow engraftment [40]. Thymic
exposure to HLA-B27 was therefore not necessary but T
cells were required for disease induction [41]. Somewhat
surprisingly though, T cells from HLA-B27 transgenic rats
of disease prone lines were not able or necessary to induce
disease in irradiated nontransgenic recipients [41]. Further
evidence arguing against a traditional role for cytotoxic T cell
recogniton of HLA-B27 was the demonstration that CD4+ T
cells were more eﬃcient than CD8+ T cells in transferring
disease and that CD8+ T cells displayed a nonactivated profile
in disease-prone strains [42]. A distinct lack of CD8+ T
cell involvement in AS was further confirmed by the recent
studies in CD8 knockouts in the HLA-B27 rat transgenics
[43].
Bone marrow-derived macrophages (BMDMs) derived
from HLA-B27-transgenic rats with inflammatory arthritis
were demonstrated to exhibit cellular stress responses in the
form of the UPR expressing elevated levels of XBP-1s [44].
However, the generation of high copy number HLA-B27.
human β2m rat transgenic model, designed to “improve
the folding” of HLA-B27 did not alleviate, but instead,
exacerbated skeletal disease. This transgenic rat did not
develop the colitis that is a common feature of the rat “AS-
like” disease suggesting that HLA-B27 misfolding could par-
ticipate in distinct forms or facets of inflammatory arthritic
disease [45]. However, analysis of transgenic animals under
conditions enhancing human β2m expression as well as
HLA-B27 heavy chain did demonstrate UPR activation
[46].
A major conundrum in the generation of AS animal
models is that several HLA-B27 transgenic mouse strains
remain healthy. However, this could simply reflect the
genetic backgrounds of the strains that were chosen for
these studies. Some mouse strains do develop a form
of inflammatory arthritis that has been linked to MHC
class I molecules. ANKENT, a spontaneous and progres-
sive ankylosing enthesopathy aﬀecting ankle/tarsal joints
of ageing mice, demonstrates both MHC and non-MHC
linked predisposition, male predominance, and histologi-
cal enthesitis. The mouse H-2k haplotype appears to be
an important risk factor, and the introduction of HLA-
B∗2702 increased the incidence of joint tarsal ankylosis [47–
49]. Also, disrupting the MHC class I pathway either by
knocking out the light chain β2m or TAP (which actively
transports peptides into the ER lumen for MHC class I
presentation) can lead to the spontaneous development
of a mild arthritis on some mouse genetic backgrounds.
These latter observations were made independent of HLA-
B27, but support the idea that misfolding of MHC class I
molecules can lead to a proinflammatory arthritic phenotype
[50].
4 International Journal of Rheumatology
Cys67
Cys203
Cys259
Cys164
Cys101
β2 m
Peptide
(a)
Val152
His114
Asp77
Asp116
Cys164
Cys101
Cys67
(b)
Asp77
Asp116
His114
Val152
(c)
Cys164
Cys101
Cys67
(d)
Figure 2: HLA-B27 structure. (a) Ribbon structure of HLA-B27 heavy chain in association with β2m and peptide. Structurally conserved
cysteines at positions 101, 164, 203, and 258 and the unpaired cysteine at p67 are highlighted by Van der Waals radii. (b) Overhead view of
the HLA-B27 antigen binding groove highlighting Cys67 and residues (His114, Asp116, Asp77, and Val152) which are polymorphic between
the disease-associated HLA-B∗2705 and nondisease-associated HLA-B∗2706 subtypes. (c) Head on view of the F pocket of the HLA-B27
antigen binding groove. His114 and Asp116 make up the floor of the F pocket, whilst Val152 and Asp77 can contribute to the interaction
between HLA-B27 and the carboxy-terminus of the associated peptide. (d) Overhead view of the HLA-B27 antigen binding groove, with
Cys67 (Van der Waals radii) and surrounding residues (ball and stick) are depicted, which are unique to HLA-B27 and contribute to the B
pocket of HLA-B27.
5. The Misfolding Hypothesis and Biochemical
Characteristics of HLA-B27
Biochemical analysis over the last 10 years has demonstrated
that HLA-B27 displays several characteristics that, to date,
set it apart from most other MHC class I molecules. The
relationship between ER stress pathways and HLA-B27 was
postulated following biochemical observations demonstrat-
ing that HLA-B27 exhibited an enhanced tendency tomisfold
[9] and was susceptible to aggregation [51].
A combination of residues in the B pocket (which binds
the N-terminal motif of MHC class I associated peptides)
were initially recognised as characteristic to HLA-B27 when
compared to other B alleles. These included the residues,
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Figure 3: Schematic outline of a hypothetical model of HLA-B27-
induced inflammatory arthritis by misfolding and/or dimerisation.
HLA-B27 matures slowly resulting in enhanced formation of aggre-
gate structures, which can potentially induce ER stress responses
and activate proinflammatory cytokine production. ER stress can
be perpetuated by further proinflammatory cytokine production,
and this can lead to the development of inflammatory arthritis.
His9, Thr24, Glu45, Cys67, Lys70, Ala71, and Gln97, which
line the B pocket and accommodate the second anchor
residue of associated peptides. This observation was thought
to support the idea that HLA-B27-specific arthritogenic pep-
tides could be presented. However, expressing a combination
of these residues to other MHC class I molecules resulted in
enhanced misfolding of non-SpA-associated HLA molecules
[9, 52].
If SpA predisposition is related to molecular structure,
then specific residues must be involved that diﬀer between
the AS predisposing and the HLA-B27 subtypes not asso-
ciated with AS. Two such HLA-B27 subtypes, HLA-B∗2706
and 09, exhibit a weak or no association with the SpAs,
but these predominantly diﬀer at residues constituting the
F pocket at position (p) 114–116, which bind the peptide
anchor motif at p9 [53] (Figures 2(b) and 2(c)). These struc-
tural diﬀerences would suggest that peptide presentationmay
play a significant role in SpA development. However, peptide
elution and sequencing analysis have revealed that there is
significant overlap in the peptides bound by HLA-B∗2709
and 06 and disease-associated subtypes [54]. Biochemical
analysis does reveal that these subtypes exhibit significant
diﬀerences in their folding and misfolding characteristics
[55–57]. It must be noted that the capacity of HLA-B27
subtypes to form dimers and their relationship to the
misfolding hypothesis has yet to be fully tested. The recent
genetic association between the Endoplasmic Reticulum
Amino Peptidase (ERAP1) [7, 58], which participates in the
generation ofMHC class I associated peptides, may support a
role for the peptide repertoire in determining the misfolding
status of HLA-B27.
In addition to the enhanced propensity to misfold,
it was observed that HLA-B27 formed aggregates when
purified as a recombinant protein [51]. This observation
was later confirmed in vivo by several laboratories, which
detected both ER resident and cell surface dimers [52, 59–61]
(Figure 4). HLA-B27 dimers were demonstrated to correlate
with disease incidence in theHLA-B27 transgenic rat models,
thus suggesting that these aggregate structures could well
indeed be responsible for the “toxicity gain of function”
[62]. Intriguingly, HLA-B27 dimeric structures that form
within the ER, do not traﬃc through the secretory pathway,
whilst cell surface dimers appear to arise from recycling
HLA-B27molecules [59, 61] (Figure 4). Originally, HLA-B27
dimerisation was proposed to occur through an unpaired
cysteine at p67, which forms part of the B pocket of the
peptide binding groove (Figures 2(a) and 2(d)) [51]. It
appears that Cys67 has a more significant role in dimerisa-
tion at the cell surface, whilst those within the ER can form
through the structurally conserved cysteine at p164 [52, 59]
(Figure 4). Transgenic rats expressing a mutant HLA-B27
molecule lacking Cys67 continue to develop disease but
with a lower prevalence [6]. Thus, whether Cys67 plays a
significant role in dimer formation and whether HLA-B27
dimers can be used as markers for SpA development remain
unresolved.
HLA-B27 heavy chain dimerisation within the ER
appears to be influenced by the maturation kinetics of HLA-
B27 [52] and can be induced following diﬀerentiation of
the dendritic-like cell line KG1.1 [63]. These observations
suggested that the slow maturation rate of HLA-B27 allows
for inappropriate disulfide linkages to be made. These aggre-
gates can form under physiological conditions, in cell types
thought to participate in disease development and under
some conditions such as those where MHC class I expression
is upregulated. Other HLA-B27 dimeric structures have been
reported, which depend on the cytoplasmic-located cys325
[64].
Thus the biochemical observations, outlined above, and
much of the data relating to animal models of inflammatory
arthritis suggest that the biosynthesis of HLA-B27 plays a
significant role in disease development.
6. Is Pathogenicity Related to
HLA-B27 Misfolded Monomeric and/or
Dimeric Molecules?
Recently, certain disorders have been categorised as protein
misfolding/conformational diseases, which are characterised
by both the loss of function associated with specific protein
mutations and “gain of toxicity function” as a result of inap-
propriate folding. Human disorders attributed to the loss of
function of proteins due to mutations, such as cystic fibrosis,
or additional gain of toxic function attributed to misfolding
and/or aggregation such as neurodegenerative disorders
and amyloidosis, have been categorised as conformational
diseases [65]. HLA-B27 possesses the two characteristics
shared by proteins implicated in conformational diseases,
that is, the ability to misfold and aggregate into dimers
(Figure 3).
It remains undetermined whether HLA-B27 heavy chain
misfolding, the formation of dimers, or both are respon-
sible for ER stress induction and/or participate in AS
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Figure 4: Schematic illustrating that ER resident and cell surface dimers are not related. ER resident dimers can form via C67-C67 or C164-
C164 disulfide bonds, but do not transit out oﬀ the ER. Cell surface dimers are thought to form following the recycling of fully folded
HLA-B27 cell surface molecules through the endocytic pathway before being reexpressed as dimers mediated by C67-C67 interactions.
pathogenesis. The predisposition of HLA-B27 heavy chain to
misfolding can be viewed as the precursor to dimerisation.
HLA-B∗2705 heavy chain has been demonstrated to exist
in several conformations in vivo [66] with each form exhibit-
ing diﬀerent redox states [66, 67]. A comparison of disease-
associated and nonassociated subtypes indicated that HLA-
B∗2706 and 09 subtype heavy chains were less susceptible to
misfolding on the basis of their accessibility to thiol modify-
ing reagents [66]. MHC class I molecule dimerisation is not
unique to HLA-B27 and has been reported for other HLA
alleles [68–70]. Other HLA molecules can dimerise either
under slow folding conditions or when overexpressed ([52]
and our unpublished data). Thus, this raises the question,
if other HLA class I molecules can dimerise, why are HLA-
B27 dimers detectable at steady state? It is possible that HLA-
B27 disulfide bonded heavy chain-dimeric structures could
be less susceptible to degradation. Such resistance to degra-
dation could reflect complex conformations attained due
to both structurally conserved cysteines and the unpaired
cysteines at p67, 308, and 325. Misfolded MHC class I heavy
chains within the ER are degraded by the proteasome, by
a process referred to as ER-associated degradation (ERAD)
which involves misfolding protein removal from the ER to
the cytosol [71]. Studies analyzing the immunomodulatory
eﬀects of human cytomegalovirus (HCMV) gene products,
US2 and US11 [72], suggest that MHC class I molecules
can use two distinct ERAD pathways. The first involves a
degradation complex composed of Derlin 1, the AAA ATPase
p97, the E3 ubiquitin ligase, HRD1 and adaptor protein
SEL1 [73]. The second pathway is less well characterised and
uses the signal peptide peptidase and TRC8 E3 ubiquitin
ligase [74, 75]. It would appear that HLA-B27 does not
form a single distinct dimeric structure but can form
diﬀerent dimers, probably diﬀering in their conformations
[52, 61, 76]. These aggregate structures could well be
resistant or ineﬃciently disposed oﬀ by the degradation
machinery used, thus their prolonged half life could poten-
tially lead to these structures being pathogenic in a similar
but not identical mechanisms proposed for conformational
diseases.
7. Summary
The misfolding hypothesis, which attempts to explain the
association between HLA-B27 and AS, incorporates many of
the observations made both with transgenic animal models
and at the molecular biochemical level. It is possible that
certain facets of the SpAs, for instance, gut inflammation,
are more dependent on HLA-B27 misfolding. However,
it remains to be determined why certain individuals are
predisposed to AS and why certain biological sites such as
the entheses are the major targets for SpA development.
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